{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:55:11Z","timestamp":1776311711790,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS547"],"award-info":[{"award-number":["YDZJ202201ZYTS547"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11030-024-10973-y","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T07:02:42Z","timestamp":1725001362000},"page":"2143-2156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Synthesis and biological evaluation of sulfonamide derivatives containing imidazole moiety as ALK5 inhibitors"],"prefix":"10.1007","volume":"29","author":[{"given":"Shu-Yan","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Xuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-Yin","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Han","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"1","key":"10973_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41467-020-15404-8","volume":"11","author":"AJ Gunderson","year":"2020","unstructured":"Gunderson AJ, Yamazaki T, McCarty K, Fox N, Phillips M, Alice A, Blair T, Whiteford M, O\u2019Brien D, Ahmad R, Kiely MX, Hayman A, Crocenzi T, Gough MJ, Crittenden MR, Young KH (2020) TGF\u03b2 suppresses CD8+ T cell expression of CXCR3 and tumor trafficking. Nat Commun 11(1):1749. https:\/\/doi.org\/10.1038\/s41467-020-15404-8","journal-title":"Nat Commun"},{"issue":"5","key":"10973_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.cell.2044.11.016","volume":"147","author":"P Friedl","year":"2011","unstructured":"Friedl P, Alexander S (2011) Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147(5):992\u20131009. https:\/\/doi.org\/10.1016\/j.cell.2044.11.016","journal-title":"Cell"},{"issue":"12","key":"10973_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/nrd1580","volume":"3","author":"JM Yingling","year":"2004","unstructured":"Yingling JM, Blanchard KL, Sawyer JS (2004) Development of TGF-\u03b2 signaling inhibitors for cancer therapy. Nat Rev Drug Discov 3(12):1011\u20131022. https:\/\/doi.org\/10.1038\/nrd1580","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10973_CR4","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/cas.14455","volume":"111","author":"Y Yoshimatsu","year":"2020","unstructured":"Yoshimatsu Y, Wakabayashi I, Kimuro S, Takahashi N, Takahashi K, Kobayashi M, Maishi N, Podyma-Inoue KA, Hida K, Miyazono K, Watabe T (2020) TNF-\u03b1 enhances TGF-\u03b2-induced endothelial-to-mesenchymal transition via TGF-\u03b2 signal augmentation. Cancer Sci 111(7):2385\u20132399. https:\/\/doi.org\/10.1111\/cas.14455","journal-title":"Cancer Sci"},{"key":"10973_CR5","doi-asserted-by":"publisher","first-page":"105715","DOI":"10.1016\/j.bioorg.2022.105715","volume":"122","author":"GH Zheng","year":"2022","unstructured":"Zheng GH, Liu J, Guo FY, Zhang ZH, Jiang YJ, Lin YC, Lan XQ, Ren J, Wu YL, Nan JX, Jin CH, Lian LH (2022) The in vitro and in vivo study of a pyrazole derivative, J-1063, as a novel anti-liver fibrosis agent: synthesis, biological evaluation, and mechanistic analysis. Bioorg Chem 122:105715. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105715","journal-title":"Bioorg Chem"},{"key":"10973_CR6","doi-asserted-by":"publisher","first-page":"106723","DOI":"10.1016\/j.bioorg.2023.106723","volume":"139","author":"HX Yang","year":"2023","unstructured":"Yang HX, Guo FY, Lin YC, Wu YL, Nan JX, Jin CH, Lian LH (2023) Synthesis of and anti-fibrotic effect of pyrazole derivative J-1048: inhibition of ALK5 as a novel approach to liver fibrosis targeting inflammation. Bioorg Chem 139:106723. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106723","journal-title":"Bioorg Chem"},{"key":"10973_CR7","doi-asserted-by":"publisher","first-page":"112154","DOI":"10.1016\/j.ejmech.2020.112154","volume":"191","author":"H Wang","year":"2020","unstructured":"Wang H, Chen M, Sang X, You X, Wang Y, Paterson LC, Hong W, Yang X (2020) Development of small molecule inhibitors targeting TGF-\u03b2 ligand and receptor: structures, mechanism, preclinical studies and clinical usage. Eur J Med Chem 191:112154. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112154","journal-title":"Eur J Med Chem"},{"issue":"16","key":"10973_CR8","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/j.bmcl.2019.07.015","volume":"29","author":"Z Guo","year":"2019","unstructured":"Guo Z, Song X, Zhao LM, Piao MG, Quan J, Piao HR, Jin CH (2019) Synthesis and biological evaluation of novel benzo[c][1,2,5]thiadiazol-5-yl and thieno[3,2-c]-pyridin-2-yl imidazole derivatives as ALK5 inhibitors. Bioorg Med Chem Lett 29(16):2070\u20132075. https:\/\/doi.org\/10.1016\/j.bmcl.2019.07.015","journal-title":"Bioorg Med Chem Lett"},{"key":"10973_CR9","doi-asserted-by":"publisher","first-page":"112354","DOI":"10.1016\/j.ejmech.2020.112354","volume":"198","author":"G Xu","year":"2020","unstructured":"Xu G, Zhang Y, Wang H, Guo Z, Wang X, Li X, Chang S, Sun T, Yu Z, Xu T, Zhao L, Wang Y, Yu W (2020) Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-\u03b2 type 1 receptor inhibitors. Eur J Med Chem 198:112354","journal-title":"Eur J Med Chem"},{"issue":"10","key":"10973_CR10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1021\/acsmedchemlett.2c00388","volume":"13","author":"RB Kargbo","year":"2022","unstructured":"Kargbo RB (2022) ALK inhibitors for treating cancer, blood, and kidney diseases. ACS Med Chem Lett 13(10):1539\u20131541. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00388","journal-title":"ACS Med Chem Lett"},{"issue":"7791","key":"10973_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-019-1897-5","volume":"577","author":"J Su","year":"2020","unstructured":"Su J, Morgani SM, David CJ, Wang Q, Er EE, Huang YH, Basnet H, Zou Y, Shu W, Soni RK, Hendrickson RC, Hadjantonakis AK, Massagu\u00e9 J (2020) TGF-\u03b2 orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature 577(7791):566\u2013571. https:\/\/doi.org\/10.1038\/s41586-019-1897-5","journal-title":"Nature"},{"issue":"1","key":"10973_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06654-8","volume":"9","author":"A Chakravarthy","year":"2018","unstructured":"Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD (2018) TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. Nat Commun 9(1):1\u201310. https:\/\/doi.org\/10.1038\/s41467-018-06654-8","journal-title":"Nat Commun"},{"issue":"1","key":"10973_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng D, Fu M, Wang M, Wei Y, Wei X (2022) Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer 21(1):104. https:\/\/doi.org\/10.1186\/s12943-022-01569-x","journal-title":"Mol Cancer"},{"issue":"6","key":"10973_CR14","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3390\/ijms19061568","volume":"19","author":"H Ungefroren","year":"2018","unstructured":"Ungefroren H, Gieseler F, Kaufmann R, Settmacher U, Lehnert H, Rauch BH (2018) Signaling crosstalk of TGF-\u03b2\/ALK5 and PAR2\/PAR1: a complex regulatory network controlling fibrosis and cancer. Int J Mol Sci 19(6):1568. https:\/\/doi.org\/10.3390\/ijms19061568","journal-title":"Int J Mol Sci"},{"key":"10973_CR15","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.bmc.2011.03.008","volume":"19","author":"CH Jin","year":"2011","unstructured":"Jin CH, Krishnaiah M, Sreenu D, Rao KS, Subrahmanyam VB, Park CY, Son YJ, Sheen YY, Kim DK (2011) Synthesis and biological evaluation of 1-substitued-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-\u03b2 type 1 receptor kinase inhibitors. Bioorg Med Chem 19:2633\u20132640. https:\/\/doi.org\/10.1016\/j.bmc.2011.03.008","journal-title":"Bioorg Med Chem"},{"key":"10973_CR16","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.bmcl.2011.08.064","volume":"19","author":"CH Jin","year":"2011","unstructured":"Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Mohan AVN, Park CY, Son JY, Sheen YY, Kim DK (2011) Synthesis and biological evaluation of 1-substituted-3-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-\u03b1]pyridine-6-yl)pyrazoles as transforming growth factor-\u03b2 type 1 receptor kinase inhibitors. Bioorg Med Chem Lett 19:2633\u20132640. https:\/\/doi.org\/10.1016\/j.bmcl.2011.08.064","journal-title":"Bioorg Med Chem Lett"},{"key":"10973_CR17","doi-asserted-by":"publisher","first-page":"126822","DOI":"10.1016\/j.bmcl.2019.126822","volume":"30","author":"YW Li","year":"2020","unstructured":"Li YW, Li XY, Li S, Zhao LM, Ma J, Piao HR, Jiang Z, Jin CH, Jin X (2020) Synthesis and evaluation of the HIF-1\u03b1 inhibitory activity of 3(5)-substituted-4-(quinolin-4-yl)- and 4-(2-phenylpyridin-4-yl)pyrazoles as inhibitors of ALK5. Bioorg Med Chem Lett 30:126822. https:\/\/doi.org\/10.1016\/j.bmcl.2019.126822","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"10973_CR18","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1021\/jm500115w","volume":"57","author":"CH Jin","year":"2014","unstructured":"Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Rao KS, Lee HJ, Park SJ, Park HJ, Lee K, Sheen YY, Kim DK (2014) Discovery of N-((4-([1,2,4] Triazolo [1,5-\u03b1]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-Imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-\u03b2 type I receptor kinase as cancer immunotherapeutic\/antifibrotic agent. J Med Chem 57(10):4213\u20134238. https:\/\/doi.org\/10.1021\/jm500115w","journal-title":"J Med Chem"},{"key":"10973_CR19","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.2147\/DDDT.S86621","volume":"9","author":"S Herbertz","year":"2015","unstructured":"Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM (2015) Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 9:4479\u20134499. https:\/\/doi.org\/10.2147\/DDDT.S86621","journal-title":"Drug Des Devel Ther"},{"key":"10973_CR20","doi-asserted-by":"publisher","first-page":"121518","DOI":"10.1016\/j.biomaterials.2022.121518","volume":"284","author":"P Zhang","year":"2022","unstructured":"Zhang P, Qin C, Liu N, Zhou X, Chu X, Lv F, Gu Y, Yin L, Liu J, Zhou J, Huo M (2022) The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials 284:121518. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121518","journal-title":"Biomaterials"},{"issue":"3","key":"10973_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1124\/mol.65.3.744","volume":"65","author":"SD Byfield","year":"2004","unstructured":"Byfield SD, Major C, Laping NJ, Roberts AB (2004) SB-505124 is a selective inhibitor of transforming growth factor-\u03b2 type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 65(3):744\u2013752. https:\/\/doi.org\/10.1124\/mol.65.3.744","journal-title":"Mol Pharmacol"},{"key":"10973_CR22","doi-asserted-by":"publisher","first-page":"116311","DOI":"10.1016\/j.ejmech.2024.116311","volume":"269","author":"YQ Meng","year":"2024","unstructured":"Meng YQ, Ren J, Su J, Guo FY, Min JZ, Nan JX, Quan JS, Lian LH, Jin CH (2024) Synthesis and anti-liver fibrosis activity of imidazole and thiazole compounds containing amino acids. Eur J Med Chem 269:116311. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116311","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10973_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2174\/1573406417666210628144849","volume":"18","author":"LM Zhao","year":"2022","unstructured":"Zhao LM, Guo FY, Wang HM, Dou T, Qi JD, Xu WB, Piao L, Jin X, Chen FE, Piao HR, Zheng CJ, Jin CH (2022) Synthesis and evaluation of chiral rhodanine derivatives bearing quinoxalinyl imidazole moiety as ALK5 inhibitors. Med Chem 18(4):509\u2013520. https:\/\/doi.org\/10.2174\/1573406417666210628144849","journal-title":"Med Chem"},{"issue":"22","key":"10973_CR24","doi-asserted-by":"publisher","first-page":"5228","DOI":"10.1016\/j.bmcl.2015.09.058","volume":"25","author":"M Krishanaiah","year":"2015","unstructured":"Krishanaiah M, Jin CH, Sheen YY, Kim DK (2015) Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-\u03b1]pyridine-6-yl)imidazoles as inhibitors of transforming growth factor-\u03b2 type I receptor kinase. Bioorg Med Chem Lett 25(22):5228\u20135231. https:\/\/doi.org\/10.1016\/j.bmcl.2015.09.058","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10973_CR25","doi-asserted-by":"publisher","first-page":"e2400131","DOI":"10.1002\/ardp.202400131","volume":"357","author":"YX Yang","year":"2024","unstructured":"Yang YX, Guo J, Liu C, Na JX, Wu YL, Jin CH (2024) Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti-cardiac fibrosis activity. Arch Pharm 357(8):e2400131. https:\/\/doi.org\/10.1002\/ardp.202400131","journal-title":"Arch Pharm"},{"issue":"2","key":"10973_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ejmech.2008.03.024","volume":"44","author":"DK Kim","year":"2009","unstructured":"Kim DK, Jung SH, Lee HS, Dewang PM (2009) Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl) imidazoles as transforming growth factor-\u03b2 type 1 receptor kinase inhibitors. Eur J Med Chem 44(2):568\u2013576. https:\/\/doi.org\/10.1016\/j.ejmech.2008.03.024","journal-title":"Eur J Med Chem"},{"key":"10973_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejmech.2012.09.011","volume":"57","author":"M Krishnaiah","year":"2012","unstructured":"Krishnaiah M, Jin CH, Sreenu D, Subrahmanyam VB, Rao KS, Son DH, Park HJ, Kim SW, Sheen YY, Kim DK (2012) Synthesis and biological evaluation of 2-benzylamino-4(5)-(6-methylpyridin-2-yl)-5(4)-([1,2,4]triazolo[1,5-\u03b1]-pyridin-6-yl)thiazoles as transforming growth factor-\u03b2 type 1 receptor kinase inhibitors. Eur J Med Chem 57:74\u201384. https:\/\/doi.org\/10.1016\/j.ejmech.2012.09.011","journal-title":"Eur J Med Chem"},{"key":"10973_CR28","doi-asserted-by":"publisher","first-page":"113311","DOI":"10.1016\/j.ejmech.2021.113311","volume":"216","author":"YY Liu","year":"2021","unstructured":"Liu YY, Guo Z, Wang JY, Wang HM, Qi JD, Ma J, Piao HR, Jin CH, Jin X (2021) Synthesis and evaluation of the eptithelial-to-mesenchymal inhibitory activity of indazole-derived imidazole as dual ALK5\/p38\u03b1 MAP inhibitors. Eur J Med Chem 216:113311. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113311","journal-title":"Eur J Med Chem"},{"issue":"8","key":"10973_CR29","doi-asserted-by":"publisher","first-page":"e2300110","DOI":"10.1002\/drdp.202300110","volume":"356","author":"JD Qi","year":"2023","unstructured":"Qi JD, Meng YQ, Sun J, Li WX, Zhai HX, Zhang C, Quan J, Jin CH (2023) Synthesis and antimicrobial activity evaluation of pyrazole derivatives containing the imidazo[2,1-b][1,3,4]thiadiazole moiety. Arch Pharm 356(8):e2300110. https:\/\/doi.org\/10.1002\/drdp.202300110","journal-title":"Arch Pharm"},{"issue":"4","key":"10973_CR30","doi-asserted-by":"publisher","first-page":"e202400135","DOI":"10.1002\/cbdv.202400135","volume":"21","author":"L Yang","year":"2024","unstructured":"Yang L, Jiao YX, Quan YH, Li MY, Huang XY, Jin JZ, Li S, Quan JS, Jin CH (2024) Synthesis and antimicrobial activity evaluation of pyridine derivatives containing imidazo[2,1-b][1,3,4]thiadiazole moiety. Chem Biodivers 21(4):e202400135. https:\/\/doi.org\/10.1002\/cbdv.202400135","journal-title":"Chem Biodivers"},{"key":"10973_CR31","unstructured":"Kim DK, Sheen YY, Jin CH, Park CY, Sreenu D, Rao KS, Krishnaiah M, Subrahmanyam VB (2012) Preparation of 2-pyridyl substituted imidazoles as therapeutic ALK5 and\/or ALK4 inhibitors. World Patent WO 2012002680 A2"},{"issue":"15","key":"10973_CR32","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1002\/cmdc.202100122","volume":"16","author":"FY Guo","year":"2021","unstructured":"Guo FY, Zheng CJ, Wang M, Ai J, Han LY, Yang L, Lu YF, Yang YX, Piao MG, Piao HR, Jin CM, Jin CH (2021) Synthesis and antimicrobial activity evaluation of imidazole-fused imidazo[2,1-b][1,3,4]thiadiazole analogues. ChemMedChem 16(15):2354\u20132365. https:\/\/doi.org\/10.1002\/cmdc.202100122","journal-title":"ChemMedChem"},{"issue":"11","key":"10973_CR33","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.6023\/cjoc202106015","volume":"41","author":"L Han","year":"2021","unstructured":"Han L, Zhao L, Wang H, Dou T, Guo F, Qi J, Xu W, Piao L, Jin X, Chen F, Piao H, Zheng C, Jin C (2021) Synthesis, antibacterial and antifungal evaluation of rhodanine derivatives bearing quinoxalinyl imidazole moiety as ALK5 inhibitors. Chin J Org Chem 41(11):4428\u20134436. https:\/\/doi.org\/10.6023\/cjoc202106015","journal-title":"Chin J Org Chem"},{"issue":"2","key":"10973_CR34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1021\/acs.joc.8b02515","volume":"84","author":"W Shi","year":"2018","unstructured":"Shi W, Zhou L, Mao B, Wang Q, Wang C, Zhang C, Li X, Xiao Y, Guo H (2018) Phosphine-catalyzed [3+2] annulation of \u03b2-sulfonamido-substituted enones with sulfamate-derived cyclic imines. J Org Chem 84(2):679\u2013686. https:\/\/doi.org\/10.1021\/acs.joc.8b02515","journal-title":"J Org Chem"},{"issue":"5","key":"10973_CR35","doi-asserted-by":"publisher","first-page":"e202300105","DOI":"10.1002\/cbdv.202300105","volume":"20","author":"WB Xu","year":"2023","unstructured":"Xu WB, Meng YQ, Sun J, Yang YX, Li WX, Wang MY, Piao MG, Li S, Quan J, Jin CH (2023) Synthesis and antibacterial activity evaluation of imidazole derivatives containing 6-methylpyridine moiety. Chem Biodivers 20(5):e202300105. https:\/\/doi.org\/10.1002\/cbdv.202300105","journal-title":"Chem Biodivers"},{"issue":"1","key":"10973_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/0115734064248204230919074743","volume":"20","author":"WB Xu","year":"2024","unstructured":"Xu WB, Li S, Zheng CJ, Yang YX, Zhang C, Jin CH (2024) Synthesis and evaluation of imidazole derivatives bearing imidazo[2,1-b][1,3,4]thiadiazole moiety as antibacterial agent. Med Chem 20(1):40\u201351. https:\/\/doi.org\/10.2174\/0115734064248204230919074743","journal-title":"Med Chem"},{"issue":"9","key":"10973_CR37","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1016\/j.bmc.2014.03.022","volume":"22","author":"CH Jin","year":"2014","unstructured":"Jin CH, Krishnaiah M, Sreenu D, Subrahmanyam VB, Park HJ, Park SJ, Sheen YY, Kim DK (2014) 4-([1,2,4]Triazolo[1,5-\u03b1]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-\u03b2 type I receptor kinase. Bioorg Med Chem 22(9):2724\u20132732. https:\/\/doi.org\/10.1016\/j.bmc.2014.03.022","journal-title":"Bioorg Med Chem"},{"key":"10973_CR38","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ejmech.2016.12.005","volume":"126","author":"T Mohamed","year":"2017","unstructured":"Mohamed T, Rao PPN (2017) 2,4-Disubstituted quinazolines as amyloid-\u03b2 aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies. Eur J Med Chem 126:823\u2013843. https:\/\/doi.org\/10.1016\/j.ejmech.2016.12.005","journal-title":"Eur J Med Chem"},{"key":"10973_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejmech.2019.07.013","volume":"180","author":"WJ Zhu","year":"2019","unstructured":"Zhu WJ, Cui BW, Wang HM, Nan JX, Piao HR, Lian LH, Jin CH (2019) Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl-pyridin-2-yl) pyrazole and 3(5)-(6-methylpyridin-2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl) pyrazole derivatives. Eur J Med Chem 180:15\u201327. https:\/\/doi.org\/10.1016\/j.ejmech.2019.07.013","journal-title":"Eur J Med Chem"},{"key":"10973_CR40","doi-asserted-by":"publisher","first-page":"114734","DOI":"10.1016\/j.ejmech.2022.114734","volume":"243","author":"J Liu","year":"2022","unstructured":"Liu J, Li H, He Q, Chen K, Chen Y, Zhong R, Li H, Fang S, Liu S, Lin S (2022) Design, synthesis, and biological evaluation of tetrahedroquinoline amphiphiles as membrane-targeting antimicrobials against pathogenic bacteria and fungi. Eur J Med Chem 243:114734. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114734","journal-title":"Eur J Med Chem"},{"issue":"17","key":"10973_CR41","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1016\/j.ejca.2011.07.007","volume":"47","author":"CY Park","year":"2011","unstructured":"Park CY, Son JY, Jin CH, Nam JS, Kim DK, Sheen YY (2011) EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur J Cancer 47(17):2642\u20132653. https:\/\/doi.org\/10.1016\/j.ejca.2011.07.007","journal-title":"Eur J Cancer"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10973-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-10973-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-10973-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T12:20:26Z","timestamp":1747311626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-10973-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10973"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-10973-y","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}